Clinical Trial

Treatment of Enterococcus Faecalis Bacterem

Study acronym: E-faecalis
Recruiting
View on ClinicalTrials.gov →
Summary
Enterococcus faecalis is a germ frequently responsible for bacteremia which can be severe with 15-25% risk of mortality and 26% risk of infectious endocarditis. There is no recommendation for the treatment of "simple" Enterococcus faecalis bacteremia (meaning without infectious endocarditis at diagnosis), nor studies comparing monotherapy versus combination antibiotic therapy. Our main objective is to study the impact on mortality of bacteriostatic monotherapy and bactericidal combination antibiotic therapy in patients with Enterococcus faecalis bacteremia. We aim to also study the mortality up to three months, the failures of treatment, the modalities of treatment, the renal toxicity and the bacterial resistance.
Trial Details
NCT Number NCT07299539
Lead Sponsor University Hospital, Strasbourg, France
Conditions Enterococcus Faecalis Bacteremia
Enrollment 700 participants
Start Date 2024-02-24
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-23